Exhibit 99.1 Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and$2.83 Billion, Representing Year-Over-Year Growth of 29% and 22%, Respectively INGREZZA (valbenazine) Full Year 2026 Net Product Sales Guidance of $2.7 -$2.8 Billion ® SAN DIEGO, Feb. 11, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourt ...